MX2010005013A - Composiciones intranasales. - Google Patents

Composiciones intranasales.

Info

Publication number
MX2010005013A
MX2010005013A MX2010005013A MX2010005013A MX2010005013A MX 2010005013 A MX2010005013 A MX 2010005013A MX 2010005013 A MX2010005013 A MX 2010005013A MX 2010005013 A MX2010005013 A MX 2010005013A MX 2010005013 A MX2010005013 A MX 2010005013A
Authority
MX
Mexico
Prior art keywords
apomorphine
intranasal compositions
cyclodextrin
poloxamer
parkinson
Prior art date
Application number
MX2010005013A
Other languages
English (en)
Inventor
Yu-Hui Cheng
Peter Watts
Original Assignee
Archimedes Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archimedes Dev Ltd filed Critical Archimedes Dev Ltd
Publication of MX2010005013A publication Critical patent/MX2010005013A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona una formulación acuosa líquida para la administración intranasal de apomorfina, que comprende: (a) cuando menos alrededor de 15 mg/ml de apomorfina; y (b) un agente de solubilización seleccionado de (i) cuando menos un copolimero de polioxietileno-polioxipropileno (poloxámero); (ii) cuando menos una ciclodextrina, y (iii) cuando menos una ciclodesgrina junto con quitosán. Las formulaciones de la invención se pueden usar en el tratamiento/manejo del mal de Parkinson.
MX2010005013A 2007-11-09 2008-11-10 Composiciones intranasales. MX2010005013A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07254426A EP2057982A1 (en) 2007-11-09 2007-11-09 Intranasal compositions
PCT/GB2008/003782 WO2009060226A1 (en) 2007-11-09 2008-11-10 Intranasal compositions

Publications (1)

Publication Number Publication Date
MX2010005013A true MX2010005013A (es) 2010-05-27

Family

ID=39052379

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005013A MX2010005013A (es) 2007-11-09 2008-11-10 Composiciones intranasales.

Country Status (21)

Country Link
US (1) US8309108B2 (es)
EP (2) EP2057982A1 (es)
JP (1) JP5530931B2 (es)
KR (1) KR101522529B1 (es)
CN (1) CN101883555B (es)
AU (1) AU2008326220B2 (es)
BR (1) BRPI0819115A2 (es)
CA (1) CA2705153C (es)
CY (1) CY1113824T1 (es)
DK (1) DK2214640T3 (es)
ES (1) ES2398267T3 (es)
HK (1) HK1146711A1 (es)
HR (1) HRP20121036T1 (es)
MX (1) MX2010005013A (es)
NZ (1) NZ585107A (es)
PL (1) PL2214640T3 (es)
PT (1) PT2214640E (es)
SI (1) SI2214640T1 (es)
TW (1) TWI426928B (es)
WO (1) WO2009060226A1 (es)
ZA (1) ZA201003172B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
ES2715028T3 (es) * 2012-06-05 2019-05-31 Neuroderm Ltd Composiciones que comprenden apomorfina y ácidos orgánicos y sus usos
EP3597178A1 (en) * 2012-06-21 2020-01-22 Phosphorex Inc. Nanoparticles of indirubin, derivatives thereof and methods of making and using same
GB201217419D0 (en) * 2012-09-28 2012-11-14 Innotesto Bvba Improvements in or relating to oromucosal apomorphine compositions
ES2860526T3 (es) 2013-07-19 2021-10-05 Boehringer Ingelheim Vetmedica Gmbh Derivados de ciclodextrina eterificada conservados que contienen una composición farmacéutica acuosa líquida
PL2925305T3 (pl) 2013-12-04 2017-07-31 Boehringer Ingelheim Vetmedica Gmbh Ulepszone kompozycje farmaceutyczne pimobendanu
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
GB201912686D0 (en) * 2019-09-04 2019-10-16 Reown Pharma Inc Pharmaceutical composition
CN115804754A (zh) * 2022-12-16 2023-03-17 广州新济药业科技有限公司 ***鼻喷剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9103824D0 (en) * 1991-02-23 1991-04-10 Fisons Ag Formulation
DK0865789T3 (da) 1993-03-26 2005-07-18 Franciscus Wilhelmus He Merkus Farmaceutiske præparater til intranasal administration af dihydroergotamin
GB9416884D0 (en) 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
EP0834308A1 (en) * 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
NZ504786A (en) * 1997-12-02 2005-07-29 West Pharm Serv Drug Res Ltd Sustained release compositions for nasal administration of drugs for treating erectile disfunction and parkinson's disease
US6436950B1 (en) 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) * 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0403938D0 (en) * 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution

Also Published As

Publication number Publication date
HRP20121036T1 (hr) 2013-01-31
EP2214640A1 (en) 2010-08-11
US8309108B2 (en) 2012-11-13
PT2214640E (pt) 2013-01-16
CN101883555B (zh) 2012-07-11
SI2214640T1 (sl) 2013-02-28
US20100249170A1 (en) 2010-09-30
JP2011503044A (ja) 2011-01-27
KR20100094980A (ko) 2010-08-27
WO2009060226A1 (en) 2009-05-14
HK1146711A1 (en) 2011-07-08
EP2214640B1 (en) 2012-10-24
CA2705153A1 (en) 2009-05-14
NZ585107A (en) 2012-05-25
CY1113824T1 (el) 2016-07-27
KR101522529B1 (ko) 2015-05-26
PL2214640T3 (pl) 2013-03-29
ZA201003172B (en) 2012-10-31
AU2008326220A1 (en) 2009-05-14
CN101883555A (zh) 2010-11-10
AU2008326220B2 (en) 2013-05-23
BRPI0819115A2 (pt) 2015-07-07
AU2008326220A2 (en) 2010-11-04
CA2705153C (en) 2016-05-24
TW200936179A (en) 2009-09-01
TWI426928B (zh) 2014-02-21
DK2214640T3 (da) 2013-02-04
EP2057982A1 (en) 2009-05-13
JP5530931B2 (ja) 2014-06-25
ES2398267T3 (es) 2013-03-15

Similar Documents

Publication Publication Date Title
MX2010005013A (es) Composiciones intranasales.
ECSP088240A (es) Composición de trazodona para administración una vez por día
WO2010047765A8 (en) Nanostructures for drug delivery
WO2009091576A3 (en) Parenteral formulations of dopamine agonists
WO2007077561A3 (en) Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
AR058620A1 (es) Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo
MX2008011085A (es) Composiciones antimicrobianas y metodos para sellar cateteres.
WO2012027065A3 (en) Combination therapy for treatment of disease
BR112015023391A8 (pt) formulações de conjugados anticorpo-droga anti-egfr
WO2007093450A3 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
WO2007027941A3 (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
WO2008008364A3 (en) Enhanced stability phenylephrine liquid compositions
MA31898B1 (fr) Compositions pharmaceutiques
EA200801275A1 (ru) Стабилизированные составы карбоната лантана
WO2005112633A3 (en) Compounds and compositions for delivering active agents
HK1113971A1 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2010021607A3 (en) Pharmaceutical formulation
MX2010005012A (es) Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor.
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2007085629A3 (en) Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents
WO2008003050A3 (en) Gallium nitrate formulations
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma

Legal Events

Date Code Title Description
FG Grant or registration